Holen Sie sich die Stockscreener-App
129.79
2.23%
-2.96
Vorhandelsmarkt:
129.77
-0.02
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$132.75
Offen:
$132.585
24-Stunden-Volumen:
3.59M
Relative Volume:
2.13
Marktkapitalisierung:
$19.02B
Einnahmen:
$9.82B
Nettoeinkommen (Verlust:
$1.48B
KGV:
12.81
EPS:
10.13
Netto-Cashflow:
$2.30B
1W Leistung:
+3.16%
1M Leistung:
+8.01%
6M Leistung:
-19.20%
1J Leistung:
-41.02%
1-Tages-Spanne:
$129.62
$132.59
1-Wochen-Bereich:
$125.89
$132.94
52-Wochen-Spanne:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
129.79 | 18.43B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
737.67 | 640.72B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.21 | 367.98B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.11 | 323.71B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.76 | 222.69B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.50 | 299.26B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
California State Teachers Retirement System Buys 2,811 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Toronto Dominion Bank Has $11.11 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
First County Bank CT Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Farmers Trust Co. Buys 2,012 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
William Blair Brokers Lower Earnings Estimates for Biogen - MarketBeat
Lighthouse Financial LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Centre Asset Management LLC Has $7.79 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Auxier Asset Management Sells 2,136 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Lansforsakringar Fondforvaltning AB publ Invests $7.38 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Mackenzie Financial Corp - MarketBeat
GF Fund Management CO. LTD. Makes New $5.24 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Progressive Supranuclear Palsy Treatment Market Set to Witness GrowthBiogen, AbbVie - openPR.com
PKO Investment Management Joint Stock Co Purchases New Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen and City Therapeutics partner to develop RNAi therapies - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by USS Investment Management Ltd - MarketBeat
Siemens Fonds Invest GmbH Grows Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Public Employees Retirement System of Ohio Sells 2,866 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Voloridge Investment Management LLC Invests $23.20 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $234.55 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Tauopathies Treatment Market Detailed in New Research ReportBiogen, AbbVie - openPR.com
Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com
Recombinant Dna Technology Market Generated Opportunities, - openPR.com
In Vitro Monoclonal Antibodies Market is expected to reach US$ - openPR.com
Biogen and City Therapeutics to develop RNAi therapy - Yahoo Finance
Biogen and City Therapeutics partner to advance RNAi therapies - World Pharmaceutical Frontiers
Biogen Inc. (NASDAQ:BIIB) Holdings Lifted by Quantinno Capital Management LP - MarketBeat
Woodline Partners LP Boosts Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential - Investing.com
Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential By Investing.com - Investing.com UK
Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal - Yahoo Finance
Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal - simplywall.st
Biogen partners with John Maraganore’s new RNAi startup - The Business Journals
Biogen (BIIB) Partners with City Therapeutics for RNAi Therapies - GuruFocus
Biogen strikes RNAi deal with City; Aurion withdraws IPO - BioPharma Dive
City hits the town with $1B-plus deal with Biogen - BioWorld MedTech
Biogen and City Therapeutics collaborate on RNAi meds - The Pharma Letter
Biogen taps City Therapeutics in RNAi deal worth up to $1B - Endpoints News
Biogen (BIIB) Collaborates with City Therapeutics on RNAi Therap - GuruFocus
Biogen and City Therapeutics Announce Strategic Research Collabo - GuruFocus
Biogen (BIIB) Collaborates with City Therapeutics on RNAi Therapies | BIIB Stock News - GuruFocus
Biogen Partners City Therapeutics To Develop Select Novel RNAi Therapies - Nasdaq
Biogen And City Therapeutics Announce Strategic Research Collaboration To Develop Select Novel Rnai-Based Therapies - marketscreener.com
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies | BIIB Stock News - GuruFocus
Biogen Inc. and City Therapeutics Announce Strategic Collaboration to Develop Novel RNAi Therapies - Nasdaq
Biogen and City Therapeutics Announce Strategic Research - GlobeNewswire
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies - Biogen
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):